新的可溶性csf - 1r -二聚体突变蛋白增强了CSF-1和IL-34的捕获,可减少胸膜间皮瘤中抑制性肿瘤相关巨噬细胞。

IF 10.3 1区 医学 Q1 IMMUNOLOGY
Noémie Joalland, Agnès Quéméner, Sophie Deshayes, Romain Humeau, Mike Maillasson, Héloïse LeBihan, Apolline Salama, Judith Fresquet, Séverine Remy, Erwan Mortier, Christophe Blanquart, Carole Guillonneau, Ignacio Anegon
{"title":"新的可溶性csf - 1r -二聚体突变蛋白增强了CSF-1和IL-34的捕获,可减少胸膜间皮瘤中抑制性肿瘤相关巨噬细胞。","authors":"Noémie Joalland, Agnès Quéméner, Sophie Deshayes, Romain Humeau, Mike Maillasson, Héloïse LeBihan, Apolline Salama, Judith Fresquet, Séverine Remy, Erwan Mortier, Christophe Blanquart, Carole Guillonneau, Ignacio Anegon","doi":"10.1136/jitc-2024-010112","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Colony stimulating factor-1 receptor (CSF-1R) and its ligands CSF-1 and interleukin (IL)-34 have tumorigenic effects through both induction of suppressive macrophages, and survival/proliferation of tumor cells. In addition, the IL-34 tumorigenic effect can also be mediated by its other receptors, protein-tyrosine phosphatase zeta, Syndecan-1 (CD138) and triggering receptor expressed on myeloid cells 2. Small tyrosine kinase inhibitors are used to block CSF-1R signaling but lack specificity. Neutralizing anti-CSF-1 and/or IL-34 antibodies have been proposed, but their effects are limited. Thus, there is a need for a more specific and yet integrative approach.</p><p><strong>Methods: </strong>A human mutated form of the extracellular portion of CSF-1R was in silico modelized to trap both IL-34 and CSF-1 with higher affinity than the wild-type CSF-1R by replacing the methionine residue at position 149 with a Lysine (<sub>M149K</sub>). The extracellular portion of the mutated CSF-1R M149K was dimerized using the immunoglobulin Fc sequence of a silenced human IgG1 (sCSF-1R<sub>M149K</sub>-Fc). Signaling through CSF-1R, survival of monocytes and differentiation of suppressive macrophages were analyzed using pleural mesothelioma patient's samples and mesothelioma/macrophage spheroids in vitro and in vivo in the presence of sCSF-1R<sub>M149K</sub>-Fc or sCSF-1R-Fc wild type control (sCSF-1R<sub>WT</sub>-Fc).</p><p><strong>Results: </strong>We defined that the D1 to D5 domains of the extracellular portion of CSF-1R were required for efficient binding to IL-34 and CSF-1. The mutein sCSF-1R<sub>M149K</sub>-Fc trapped with higher affinity than sCSF-1R<sub>WT</sub>-Fc both CSF-1 and IL-34 added in culture and naturally produced in mesothelioma pleural effusions. sCSF-1R<sub>M149K</sub>-Fc inhibited CSF-1R signaling, survival and differentiation of human suppressive macrophage in vitro and in vivo induced by pleural mesothelioma cells. Neutralization of IL-34 and CSF-1 by sCSF-1R<sub>M149K</sub>-Fc also resulted in higher killing of pleural mesothelioma cells by a tumor-specific CD8<sup>+</sup> T cell clone in mesothelioma/macrophage spheroids.</p><p><strong>Conclusions: </strong>sCSF-1R<sub>M149K</sub>-Fc efficiently traps both CSF-1 and IL-34 and inhibits CSF-1R signaling, monocyte survival and suppressive macrophage differentiation induced by pleural mesothelioma cells producing CSF-1 and IL-34, as well as restores cytotoxic T-cell responses. sCSF-1R<sub>M149K</sub>-Fc has therapeutic potential vs other therapies under development targeting single components of this complex cytokine pathway involved in cancer.</p>","PeriodicalId":14820,"journal":{"name":"Journal for Immunotherapy of Cancer","volume":"13 3","pages":""},"PeriodicalIF":10.3000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927444/pdf/","citationCount":"0","resultStr":"{\"title\":\"New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma.\",\"authors\":\"Noémie Joalland, Agnès Quéméner, Sophie Deshayes, Romain Humeau, Mike Maillasson, Héloïse LeBihan, Apolline Salama, Judith Fresquet, Séverine Remy, Erwan Mortier, Christophe Blanquart, Carole Guillonneau, Ignacio Anegon\",\"doi\":\"10.1136/jitc-2024-010112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Colony stimulating factor-1 receptor (CSF-1R) and its ligands CSF-1 and interleukin (IL)-34 have tumorigenic effects through both induction of suppressive macrophages, and survival/proliferation of tumor cells. In addition, the IL-34 tumorigenic effect can also be mediated by its other receptors, protein-tyrosine phosphatase zeta, Syndecan-1 (CD138) and triggering receptor expressed on myeloid cells 2. Small tyrosine kinase inhibitors are used to block CSF-1R signaling but lack specificity. Neutralizing anti-CSF-1 and/or IL-34 antibodies have been proposed, but their effects are limited. Thus, there is a need for a more specific and yet integrative approach.</p><p><strong>Methods: </strong>A human mutated form of the extracellular portion of CSF-1R was in silico modelized to trap both IL-34 and CSF-1 with higher affinity than the wild-type CSF-1R by replacing the methionine residue at position 149 with a Lysine (<sub>M149K</sub>). The extracellular portion of the mutated CSF-1R M149K was dimerized using the immunoglobulin Fc sequence of a silenced human IgG1 (sCSF-1R<sub>M149K</sub>-Fc). Signaling through CSF-1R, survival of monocytes and differentiation of suppressive macrophages were analyzed using pleural mesothelioma patient's samples and mesothelioma/macrophage spheroids in vitro and in vivo in the presence of sCSF-1R<sub>M149K</sub>-Fc or sCSF-1R-Fc wild type control (sCSF-1R<sub>WT</sub>-Fc).</p><p><strong>Results: </strong>We defined that the D1 to D5 domains of the extracellular portion of CSF-1R were required for efficient binding to IL-34 and CSF-1. The mutein sCSF-1R<sub>M149K</sub>-Fc trapped with higher affinity than sCSF-1R<sub>WT</sub>-Fc both CSF-1 and IL-34 added in culture and naturally produced in mesothelioma pleural effusions. sCSF-1R<sub>M149K</sub>-Fc inhibited CSF-1R signaling, survival and differentiation of human suppressive macrophage in vitro and in vivo induced by pleural mesothelioma cells. Neutralization of IL-34 and CSF-1 by sCSF-1R<sub>M149K</sub>-Fc also resulted in higher killing of pleural mesothelioma cells by a tumor-specific CD8<sup>+</sup> T cell clone in mesothelioma/macrophage spheroids.</p><p><strong>Conclusions: </strong>sCSF-1R<sub>M149K</sub>-Fc efficiently traps both CSF-1 and IL-34 and inhibits CSF-1R signaling, monocyte survival and suppressive macrophage differentiation induced by pleural mesothelioma cells producing CSF-1 and IL-34, as well as restores cytotoxic T-cell responses. sCSF-1R<sub>M149K</sub>-Fc has therapeutic potential vs other therapies under development targeting single components of this complex cytokine pathway involved in cancer.</p>\",\"PeriodicalId\":14820,\"journal\":{\"name\":\"Journal for Immunotherapy of Cancer\",\"volume\":\"13 3\",\"pages\":\"\"},\"PeriodicalIF\":10.3000,\"publicationDate\":\"2025-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927444/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal for Immunotherapy of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/jitc-2024-010112\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal for Immunotherapy of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/jitc-2024-010112","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:集落刺激因子-1受体(Colony stimulating factor-1 receptor, CSF-1R)及其配体CSF-1和白细胞介素(interleukin, IL)-34通过诱导抑制性巨噬细胞和肿瘤细胞的存活/增殖而具有致瘤作用。此外,IL-34的致瘤作用还可通过其其他受体介导,如蛋白酪氨酸磷酸酶zeta、Syndecan-1 (CD138)和髓细胞上表达的触发受体2。小型酪氨酸激酶抑制剂用于阻断CSF-1R信号传导,但缺乏特异性。已经提出了中和抗csf -1和/或IL-34抗体,但其作用有限。因此,需要一种更具体而又综合的方法。方法:用赖氨酸(M149K)取代149号位置的蛋氨酸残基,用硅模拟人类突变形式的CSF-1R细胞外部分,捕获IL-34和CSF-1,比野生型CSF-1R具有更高的亲和力。使用沉默的人IgG1 (sCSF-1RM149K-Fc)的免疫球蛋白Fc序列对突变的CSF-1RM149K的细胞外部分进行二聚化。采用胸膜间皮瘤患者标本和间皮瘤/巨噬细胞球体,在体外和体内研究sCSF-1RM149K-Fc或sCSF-1R-Fc野生型对照(sCSF-1RWT-Fc)存在下,通过CSF-1R信号传导、单核细胞的存活和抑制巨噬细胞的分化。结果:我们确定了CSF-1R细胞外部分的D1至D5结构域是有效结合IL-34和CSF-1所必需的。突变蛋白sCSF-1RM149K-Fc比sCSF-1RWT-Fc具有更高的亲和力,CSF-1和IL-34在培养中添加,并在间皮瘤胸膜积液中自然产生。sCSF-1RM149K-Fc在胸膜间皮瘤细胞诱导的体外和体内抑制CSF-1R信号、人抑制性巨噬细胞的存活和分化。sCSF-1RM149K-Fc中和IL-34和CSF-1也导致间皮瘤/巨噬细胞球中肿瘤特异性CD8+ T细胞克隆对胸膜间皮瘤细胞的杀伤更高。结论:sCSF-1RM149K-Fc能有效捕获CSF-1和IL-34,抑制CSF-1R信号传导、单核细胞存活和产生CSF-1和IL-34的胸膜间皮瘤细胞诱导的抑制性巨噬细胞分化,恢复细胞毒性t细胞反应。sCSF-1RM149K-Fc与其他正在开发的针对癌症中涉及的复杂细胞因子通路的单一成分的疗法相比具有治疗潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma.

Background: Colony stimulating factor-1 receptor (CSF-1R) and its ligands CSF-1 and interleukin (IL)-34 have tumorigenic effects through both induction of suppressive macrophages, and survival/proliferation of tumor cells. In addition, the IL-34 tumorigenic effect can also be mediated by its other receptors, protein-tyrosine phosphatase zeta, Syndecan-1 (CD138) and triggering receptor expressed on myeloid cells 2. Small tyrosine kinase inhibitors are used to block CSF-1R signaling but lack specificity. Neutralizing anti-CSF-1 and/or IL-34 antibodies have been proposed, but their effects are limited. Thus, there is a need for a more specific and yet integrative approach.

Methods: A human mutated form of the extracellular portion of CSF-1R was in silico modelized to trap both IL-34 and CSF-1 with higher affinity than the wild-type CSF-1R by replacing the methionine residue at position 149 with a Lysine (M149K). The extracellular portion of the mutated CSF-1R M149K was dimerized using the immunoglobulin Fc sequence of a silenced human IgG1 (sCSF-1RM149K-Fc). Signaling through CSF-1R, survival of monocytes and differentiation of suppressive macrophages were analyzed using pleural mesothelioma patient's samples and mesothelioma/macrophage spheroids in vitro and in vivo in the presence of sCSF-1RM149K-Fc or sCSF-1R-Fc wild type control (sCSF-1RWT-Fc).

Results: We defined that the D1 to D5 domains of the extracellular portion of CSF-1R were required for efficient binding to IL-34 and CSF-1. The mutein sCSF-1RM149K-Fc trapped with higher affinity than sCSF-1RWT-Fc both CSF-1 and IL-34 added in culture and naturally produced in mesothelioma pleural effusions. sCSF-1RM149K-Fc inhibited CSF-1R signaling, survival and differentiation of human suppressive macrophage in vitro and in vivo induced by pleural mesothelioma cells. Neutralization of IL-34 and CSF-1 by sCSF-1RM149K-Fc also resulted in higher killing of pleural mesothelioma cells by a tumor-specific CD8+ T cell clone in mesothelioma/macrophage spheroids.

Conclusions: sCSF-1RM149K-Fc efficiently traps both CSF-1 and IL-34 and inhibits CSF-1R signaling, monocyte survival and suppressive macrophage differentiation induced by pleural mesothelioma cells producing CSF-1 and IL-34, as well as restores cytotoxic T-cell responses. sCSF-1RM149K-Fc has therapeutic potential vs other therapies under development targeting single components of this complex cytokine pathway involved in cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer Biochemistry, Genetics and Molecular Biology-Molecular Medicine
CiteScore
17.70
自引率
4.60%
发文量
522
审稿时长
18 weeks
期刊介绍: The Journal for ImmunoTherapy of Cancer (JITC) is a peer-reviewed publication that promotes scientific exchange and deepens knowledge in the constantly evolving fields of tumor immunology and cancer immunotherapy. With an open access format, JITC encourages widespread access to its findings. The journal covers a wide range of topics, spanning from basic science to translational and clinical research. Key areas of interest include tumor-host interactions, the intricate tumor microenvironment, animal models, the identification of predictive and prognostic immune biomarkers, groundbreaking pharmaceutical and cellular therapies, innovative vaccines, combination immune-based treatments, and the study of immune-related toxicity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信